Mr Mark Howard Kelso, LCSW in Jacksonville, AR - Medicare Provider

Mr Mark Howard Kelso, LCSW is a medicare enrolled "Counselor - Mental Health" provider in Jacksonville, Arkansas. His current practice location is 1200 James Street, Jacksonville, Arkansas. You can reach out to his office (for appointments etc.) via phone at (501) 982-5000.

Mr Mark Howard Kelso is licensed to practice in * (Not Available) (license number ) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1245667237.

Contact Information

	Mr Mark Howard Kelso, LCSW
	1200 James Street, Jacksonville, AR 72076
	(501) 982-5000
	(501) 982-5007

Healthcare Provider's Profile

Full Name	Mr Mark Howard Kelso
Gender	Male
Speciality
Experience	Years
Location	1200 James Street, Jacksonville, Arkansas
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Mr Mark Howard Kelso attended and graduated from in

NPI Data:

NPI Number: 1245667237
Provider Enumeration Date: 10/04/2013
Last Update Date: 12/18/2014

Medicare PECOS Information:

PECOS PAC ID:
Enrollment ID:

Medical Identifiers

Medical identifiers for Mr Mark Howard Kelso such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1245667237	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1041C0700X	Social Worker - Clinical	697-C (Arkansas)	Secondary
101YM0800X	Counselor - Mental Health	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr Mark Howard Kelso is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr Mark Howard Kelso, LCSW 1815 Pleasant Grove Road, Jonesboro, AR 72404 Ph: (870) 933-6886	Mr Mark Howard Kelso, LCSW 1200 James Street, Jacksonville, AR 72076 Ph: (501) 982-5000

News Archive

Proving value a challenge for comparative effectiveness and pharmaceutical technologies

The Wall Street Journal reports that "an examination of one of the best-known examples of a comparative-effectiveness analysis shows how complicated such a seemingly straightforward idea can get" as officials look for savings in the health care system." One study, called Courage, "found that the most common heart surgery - a $15,000 procedure that unclogs arteries using a small scaffold or stent - usually yields no additional benefit when used with a cocktail of generic drugs in patients suffering from chronic chest pain."

UAB scientists create alternative to the use of viruses in gene therapy

A team of scientists from the Institute for Biotechnology and Biomedicine at the UAB has produced an alternative to the use of viruses in gene therapy. The researchers synthesised nanoparticles which act as artificial viruses, capable of surrounding DNA fragments and releasing them as therapeutic agents, with no biological risk, into the interior of the cells.

OrthoSensor raises $19 million in Series C Preferred Stock financing

OrthoSensor, Inc., the leader in Sensor-Assisted Surgery, announced today that it has raised $19 million in a private placement of Series C Preferred Stock. Bridger Healthcare, Ltd. and The Tullis Growth Fund, L.P. participated in the round. The proceeds will be used to drive the commercialization of VERASENSE, OrthoSensor's leading product, and expand product development activities.

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA.

Mr Mark Howard Kelso, LCSW - Medicare in Jacksonville, AR